19 results
424B5
ELTX
Elicio Therapeutics Inc.
24 May 22
Prospectus supplement for primary offering
4:02pm
volunteer study, which was designed to support clinical development in multiple indications, demonstrated ANG-3070 has a favorable safety and PK
424B3
ELTX
Elicio Therapeutics Inc.
24 May 22
Prospectus supplement
4:01pm
in a variety of animal models. A Phase 1 healthy volunteer study, which was designed to support clinical development in multiple indications
S-3
ELTX
Elicio Therapeutics Inc.
16 May 22
Shelf registration
5:23pm
in a variety of animal models. A Phase 1 healthy volunteer study, which was designed to support clinical development in multiple indications, demonstrated ANG … models. A Phase 1 healthy volunteer study, which was designed to support clinical development in multiple indications, demonstrated ANG-3070 has
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
30 Mar 22
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
4:52pm
detail positive data from the Phase 1 healthy volunteer study of ANG-3070
◦Presented preclinical data in several models of kidney and lung fibrosis
8-K
EX-99.1
4oc78lpph
12 Nov 21
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
bl2yeoko g1u4vaglxx
12 Aug 21
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
4:10pm
8-K
EX-99.1
0tg 24andp
17 May 21
Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results
6:20am
10-Q
lztr gquz
17 May 21
Quarterly report
6:03am
8-K
EX-99.1
t4hj7hjxorhwqvu98a8j
30 Mar 21
Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
5:02pm
10-K
y51ov
30 Mar 21
Annual report
5:00pm
424B4
v7nm8
5 Feb 21
Prospectus supplement with pricing info
5:12pm
DRS/A
dpooy
15 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
e1lkdv
13 May 20
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next